Key statistics
As of last trade Ligand Pharmaceuticals Inc (LGDN:FRA) traded at 105.00, -12.50% below its 52-week high of 120.00, set on Nov 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 105.00 |
---|---|
High | 105.00 |
Low | 105.00 |
Bid | 110.00 |
Offer | 112.00 |
Previous close | 105.00 |
Average volume | 90.78 |
---|---|
Shares outstanding | 18.90m |
Free float | 18.54m |
P/E (TTM) | 45.97 |
Market cap | 2.11bn USD |
EPS (TTM) | 2.43 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 15:04 GMT.
More ▼
Press releases
- Ligand to Present at Stifel 2024 Healthcare Conference
- Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
- Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
- Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
More ▼